Expression of cyclooxygenase-2, glucose transporter-1 and angiogenesis in gallbladder carcinomas and their impact on prognosis

References

• Faivre J, Forman D, Esteve J, Obradovic M, Sant M. Survival of patients with primary liver cancer, pancreatic and biliary tract cancer in Europe. EUROCARE Working Group. Eur J Cancer 1998; 34: 2184–90
   PubMed Web of Science ®Google Scholar
• Sundfor K, Lyng H, Rofstad EK. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of uterine cervix. Br J Cancer 1998; 78: 822–7
   PubMed Web of Science ®Google Scholar
• Yoshimura H, Kumar Dhar D, Kohno H, Kubota H, Fujii T, Ueda S, et al. Prognostic impact of hypoxia-inducible factors 1α and 2α in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res 2004; 10: 8554–60
   PubMed Web of Science ®Google Scholar
• Legan M, Luzar B, Ferlan Marolt V, Cör A. Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lessions. World J Gastroenterol 2006; 21: 3425–9
   Google Scholar
• Gately S. The contribution of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000; 19: 19–27
   PubMed Web of Science ®Google Scholar
• Subbaramaiah K, Danenberg AJ. Cyclooxygenase-2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003; 24: 96–102
   PubMed Web of Science ®Google Scholar
• Eberhart CE, Coffey RJ, Radhika A, Gardiell FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase-2 gene expression in colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183–8
   PubMed Web of Science ®Google Scholar
• Rao M, Yang W, Seifalian AM, Winslet MC. Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer. Int J Colorect Dis 2004; 19: 1–11
   PubMedGoogle Scholar
• von Rahden BH, Stein HJ, Pühringer F, Koch I, Langer R, Piontek G, et al. Coexpression of cyclooxygenase (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res 2005; 65: 5038–44
   PubMed Web of Science ®Google Scholar
• Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001; 3: 53–61
   PubMed Web of Science ®Google Scholar
• Koga T, Shibahara K, Kabashima A, Sumiyoshi Y, Kimura Y, Takahashi I, et al. Overexpression of cyclooxygenase-2 and tumor angiogenesis in human gastric cancer. Hepatogastroenterology 2004; 51: 1626–30
   PubMedGoogle Scholar
• von Rahden BHA, Stein HJ, Puhringer F, Koch I, Langer R, Piontek G, et al. Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res 2005; 65: 5038–44
   PubMed Web of Science ®Google Scholar
• Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 2002; 33: 708–14
   PubMed Web of Science ®Google Scholar
• Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931–4
   PubMed Web of Science ®Google Scholar
• Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9–19
   PubMed Web of Science ®Google Scholar
• Mortone T, Rosso P, Albera R, Migliaretti G, Fraire F, Pignataro L, et al. Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome. Oral Oncol 2005; 41: 147–55
   PubMedGoogle Scholar
• Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyashara R, Li M, et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001; 7: 3410–15
   PubMed Web of Science ®Google Scholar
• Kumar S, Ghellal A, Li C, Bryne G, Haboubi N, Wang JM, et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999; 59: 856–61
   PubMed Web of Science ®Google Scholar
• Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, et al. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD 105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 2003; 88: 1424–31
   PubMed Web of Science ®Google Scholar
• Sugawara Y, Makuuchi M, Harihara Y, Noie T, Inoue K, Kubota K, et al. Tumor angiogenesis in gallbladder carcinoma. Hepatogastroenterology 1999; 46: 1882–6
   Google Scholar
• Giatromanolaki A, Sivridis E, Koukourakis MI, Polychronidis A, Simopoulos C. Prognostic role of angiogenesis in operable carcinoma of gallbladder. Am J Clin Oncol 2002; 25: 38–41
   PubMedGoogle Scholar
• Zhi YH, Liu RS, Song MM, Tian Y, Long J, Tu W, et al. Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma. World J Gastroenterol 2005; 11: 3724–8
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401–10
   PubMed Web of Science ®Google Scholar
• Cooper R, Sarioglu S, Sökmen S, Füzün M, Küpelioglu A, Valentine H, et al. Glucose-transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma?. Br J Cancer 2003; 89: 870–6
   PubMed Web of Science ®Google Scholar
• Behrooz JM, Isail-Beigi F. Dual control of GLUT-1 glucose transporter gene expression by hypoxia and by inhibition of oxydative phosphorylation. J Biol Chem 1997; 272: 5555–62
   PubMedGoogle Scholar
• Furudoi A, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, et al. Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 2001; 60: 162–9
   PubMedGoogle Scholar
• Griffiths EA, Pritchard SA, Welch IM, Price PM, West CM. Is the hypoxia-inducible factor pathway important in gastric cancer?. Eur J Cancer 2005; 41: 2792–805
   PubMed Web of Science ®Google Scholar
• Ashton-Sager A, Paulino AFG, Afify AA. GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrium adenocarcinoma. Appl Immunohistochem MO Morphol 2006; 14: 187–92
   Google Scholar
• Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, et al. GLUT1 glucose transporter expression in colorectal carcinoma. Cancer 1998; 83: 34–40
   PubMed Web of Science ®Google Scholar
• Zimmerman RL, Fogt F, Burke M, Murakata LA. Assesment of GLUT-1 expression in cholangiocarcinoma, benign biliary lessions and hepatocellular carcinoma. Oncol Rep 2002; 9: 689–92
   PubMed Web of Science ®Google Scholar
• Fonsatti E, Sigalotti L, Arslan P, Altomonte M, Maio M. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Current Cancer Drug Targets 2003; 3: 427–32
   PubMed Web of Science ®Google Scholar
• Fonsatti E, Maio M. Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transl Med 2004; 2: 18
   PubMedGoogle Scholar
• Ho JW, Poon RT, Sun CK, Xue WC, Fan ST. Clinicopathological and prognostic implications of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver. World J Gastroenterol 2005; 11: 176–81
   PubMedGoogle Scholar
• Okita S, Kondoh S, Shiraishi K, Kaino S, Hatano S, Okita K. Expression of vascular endothelial growth factor correlates with tumor progression in gallbladder cancer. Int J Oncol 1998; 12: 1013–18
   PubMed Web of Science ®Google Scholar
• O'Grady A, O'Kelly P, Murphy GM, Leader M, Kay E. COX-2 expression correlates with microvessel density in non-melanoma skin cancer from renal transplant recipients and immunocompetent individuals. Hum Pathol 2004; 35: 1549–55
   PubMedGoogle Scholar
• Hemmerlein B, Galuschka L, Putzer N, Zischkau S, Heuser M. Comparative analysis of COX-2, vascular endothelial growth factor and microvessel density in human renal cell carcinoma. Histopathology 2004; 45: 603–11
   PubMedGoogle Scholar
• Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946–52
   PubMed Web of Science ®Google Scholar
• Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002; 62: 625–31
   PubMed Web of Science ®Google Scholar
• Ebert BL, Firth JD, Ratcliffes PJ. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct cis-acting sequences. J Biol Chem 1995; 270: 29083–9
   PubMed Web of Science ®Google Scholar
• Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, et al. Glucose transporter GLUT-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 2001; 7: 928–34
   PubMed Web of Science ®Google Scholar
• Minami K, Saito Y, Imamura H, Okamura A. Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 2002; 38: 51–7
   PubMed Web of Science ®Google Scholar
• Chandan VS, Faquin WC, Wilbur DC, Khurana KK. The utility of GLUT-1 immunolocalization in cell blocks. Cancer 2006; 108: 124–8
   PubMedGoogle Scholar
• Kim YW, Park YK, Yoon TY, Lee SM. Expression of the GLUT1 glucose transporter in gallbladder carcinomas. Hepatogastroenterology 2002; 49: 907–11
   PubMedGoogle Scholar
• Nakashima T, Kondoh S, Kitoh H, Ozawa H, Okita S, Harada T, et al. Vascular endothelial growth factor-C expression in human gallbladder cancer and its relationship to lymph node metastasis. Int J Mol Med 2003; 11: 33–9
   PubMedGoogle Scholar
• Aramaki M, Matsumoto T, Shibata K, Himeno Y, Yada K, Hirano S, et al. Factors influencing recurrence after surgical treatment for T2 gallbladder carcinoma. Hepatogastroenterology 2004; 51: 1609–11
   PubMedGoogle Scholar